ERBB2 and breast carcinoma: The Wilcoxon signed-rank test suggested that TILs (p = 0.043) and PD-L1 (p = 0.027) in tumor cells were significantly lower in HER2+HR− breast cancer patients in the AR+ group, as shown in Fig. 6.